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Fibrostenotic strictures are an important complication in patients with Crohn’s disease 
(CD), very often necessitating surgery. This fibrotic process develops in a genetically 
susceptible individual and is influenced by an interplay with environmental, immunolog-
ical, and disease-related factors. A deeper understanding of the genetic factors driving 
this fibrostenotic process might help to unravel the pathogenesis, and ultimately lead to 
development of new, anti-fibrotic therapy. Here, we review the genetic factors that have 
been associated with the development of fibrosis in patients with CD, as well as their 
potential pathophysiological mechanism(s). We also hypothesize on clinical implications, 
if any, and future research directions.
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iNTRODUCTiON
Crohn’s disease (CD) is a chronic, inflammatory disease of the gastrointestinal tract, which predomi-
nantly affects the distal ileum and right colon. Although many patients express an inflammatory phe-
notype at diagnosis, the natural evolution of CD is commonly a progression toward a fibrostenotic 
or penetrating disease in 60% of patients (1, 2). The pathogenesis of CD is multifactorial, including a 
genetic background (3). Genome-wide association studies and meta-analysis have identified a total 
of 200 inflammatory bowel disease (IBD) risk loci thus far (4, 5).
Transmural inflammation as seen in CD can cause irreversible changes in the intestinal archi-
tecture, over time leading to fibrotic strictures necessitating surgery in 30–50% of patients (1, 2, 6). 
Recurrence of these fibrotic lesions occurs in 23–41% of CD patients, requiring additional resec-
tions (7), which in turn reinforce the recurrence rate (8). These fibrostenotic strictures are the 
result of a failure of physiological wound healing. The activation of mesenchymal cells by cytokines, 
growth factors, and other mediators released by immune cells, epithelial cells, and mesenchymal 
cells themselves are believed to play an important role (9–11). The development of fibrosis in CD is 
influenced by various genetic, environmental, immunological, and disease-related factors (12–15). 
So far, the relative contribution of each component in the pathogenesis is not clear. This review 
aims to clarify the genetic contribution in developing fibrosis in patients with CD.
TABLe 1 | Key gene polymorphisms and their significance in intestinal fibrosis in CD.
Gene Polymorphism Association Studied population Sample sizee Reference
NOD2 rs2066844, R702W Discussed separately  
in Table 2rs2066845, G908R
rs2066847, Leu1007fsinC
ATG16L1 rs2241880, T300A Ileal disease location Australian 669–154 Fowler et al. (58)
Fibrostenotic diseasea
IL-23R rs1004819 Ileal disease locationb German 833 Glas et al. (65)
Fibrostenotic diseasea,b
CX3CR1 rs3732379, V249I/rs3732378,  
T280M
Ileocolonic disease location German 206 Brand et al. (74)
Fibrostenotic diseasea
rs3732379, V249I Fibrostenotic diseasea Caucasian 239 Sabate et al. (52)
TGF-β rs1800471, R25P Fibrostenotic diseasec Australian 235–112 Hume et al. (79)
MMP-3 −1613 5T6T Colonic disease location Dutch 134 Meijer et al. (88)
Fibrostenotic diseasea
MAGI1 rs11924265 Fibrostenotic diseased Spanish 1090–1296 Alonso et al. (96)
JAK2 rs10758669 Ileal disease location Caucasian 1528 Cleynen et al. (50)
Fibrostenotic diseased
FUT2 rs601338 Fibrostenotic diseased Belgian 647 Forni et al. (99)
IL12B rs1363670 Fibrostenotic diseased Belgian 875 Henckaerts et al. (103)
If a significant association between the given variant and disease location is found in the reference, this is mentioned in the table.
aNot corrected for disease location.
bNot significant after Bonferroni correction.
cNo longer significant after multivariate analysis taking into account disease location.
dCorrected for disease location.
eNumber of included CD patients in primary cohort − number of included CD patients in replication cohort (if applicable).
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GeNeTiCS AND FiBROSiS
There exists broad heterogeneity of published literature concern-
ing the genetic background of fibrotic CD. Below, we give an 
overview of individual variants and genes that have been associ-
ated with fibrotic disease in CD (Table 1), and we hypothesize on 
the potential pathophysiological mechanisms.
Nucleotide-Binding Oligomerization 
Domain-Containing Protein 2
The NOD2 gene is the most studied gene in relation to fibrosten-
otic disease in CD. Located in the IBD1 locus on chromosome 
16q12, it encodes CARD15, a member of the Apaf-1/NOD1 
family of CARD (caspase recruitment domain-containing 
protein) proteins (16, 17). NOD2/CARD15 is mainly expressed 
by monocytes and macrophages, where it acts as a cytosolic 
sensor for bacterial products, and is involved in apoptosis and 
activates NF-κB in response to lipopolysaccharide (LPS) binding 
at its leucine-rich repeating region (LRR) (18, 19). Moreover, the 
CARD-domain provides CARD15 the unique function to be able 
to induce interleukin 1-beta (IL-1β) processing and release (20). 
Importantly, NOD2 is also expressed in Paneth cells (21).
In the early 2000s, three NOD2 variants, including two amino 
acid substitutions (R702W in exon 4 and G908R in exon 8) 
and one frameshift mutation (Leu1007fsinC in exon 11), were 
identified as associated with CD (17, 22–25). Later on, several 
other NOD2 SNPs were found to be associated with CD, although 
the first three described still represent the strongest association 
signals. Ever since NOD2 was identified as a CD susceptibility 
gene, many genotype–phenotype studies were performed to find 
its role in defining CD disease location and behavior, but none of 
the three SNPs was uniformly found as an independent risk factor 
for developing fibrostenotic disease in CD (12, 15, 18, 19, 21, 24, 
26–53). Some genotype–phenotype studies demonstrated strong 
associations between at least one of the three NOD2 variants and 
fibrostenotic disease (19, 32, 38, 52), often independent of an 
association with small bowel disease (18, 26, 31, 37, 50) (Table 2).
The lack of uniformity concerning this topic seems mainly 
based on the small sub-analyses done in the different studies 
(Table  2). In 2004, Heresbach et  al. observed in a Northern-
French population NOD2 R702W (rs2066844) as being a 
strong predictor of fibrostenotic disease, independently of ileal 
localization of the disease (34). No other group could confirm 
this association. An association of NOD2 G908R (rs2066845) 
and fibrostenotic disease was first reported in a Spanish CD 
cohort, although fibrostenotic disease was mainly dependent on 
location of disease in the terminal ileum (33). Later on, Adler 
et al. reported in their meta-analysis G908R as being associated 
with fibrostenotic disease [pooled relative risk (RR) =  1.90] 
(47). It is important to highlight that only 12 of all included 
studies in this meta-analysis had enough data to analyze 
individual NOD2 variants, and most included studies did not 
differentiate between G908R homo- and heterozygotes. Of the 
three NOD2 variants, the Leu1007fsinsC frameshift mutation 
(rs2066847) shows the strongest association with fibrosten-
otic disease (18, 37). The same finding was also published by 
Radlmayr et  al., who moreover reported no association with 
ileal disease (28). Vavassori et  al. also noticed an association 
between Leu1007fsinC and fibrostenotic disease, although no 
correction for ileal disease involvement was made (29). Seiderer 
et al. calculated a positive predictive value (PPV) of 80% and 
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a negative predictive value (NPV) of 75% for the diagnosis of 
small bowel stenosis in clinically symptomatic patients with a 
Leu1007fsinC variant. Furthermore, they noticed 62% of their 
patients being Leu1007fsinC homo- or heterozygous needed 
surgery, whereas the need for surgical intervention in patients 
without this variant was remarkably low (53). A sub-analysis of 
another cohort with 19 patients, all Leu1007fsinC homozygous, 
identified a high-risk population, characterized by, for instance, 
long-segment stenosis, frequent need for surgery, and high risk 
for re-stenosis afterward (24). The same group confirmed these 
findings later on in a prospective study (53), whereafter the 
European IBD chip project reported the same in a retrospective 
study (n = 38) (50), as did Schnitzler et al. (51). Besides studying 
the association of individual NOD2 SNPs with a fibrostenotic 
CD phenotype, often the NOD2 SNPs are considered together. 
The pooled RR of stricturing disease with the presence of any 
NOD2 variant allele was 1.33 in a meta-analysis, including 35 
studies by Adler et al. (47). Furthermore, Lesage et al. clearly 
described the “gene dosage effect” of NOD2 SNPs: patients car-
rying two SNPs have a higher incidence of stenosis compared 
to patients with one or two wild-type alleles (26), which was 
afterward confirmed by others (31, 40, 47). Although many 
groups, thus, reported an association between NOD2 variants 
and fibrostenotic disease, several studies could not find this 
association. Louis et  al. found that only disease location and 
number of flares per year are significantly different between 
different CD phenotypes, and that ileal disease location was 
associated with a stricturing disease pattern (30). In addition, 
although NOD2 variants were associated with CD susceptibil-
ity in a Brazilian population, Baptista et  al. could not find a 
genotype–phenotype correlation (42). The biggest study looking 
into genotype–phenotype associations in IBD to date, also did 
not find an association between NOD2 and fibrotic disease, 
when considering disease location. They conclude that while 
TABLe 2 | Overview of original studies showing an association between NOD2 and fibrotic CD.
Polymorphism Association Studied population Sample size Reference
rs2066844 Fibrostenotic diseasea French 205 Heresbach et al. (34)
R702W
rs2066845 Fibrostenotic diseasec Spanish 204 Mendoza et al. (33)
G908R Fibrostenotic diseaseb Meta-analysis 8833 Adler et al. (47)
rs2066847
Leu1007fsinC
Ileal disease location North-American 201 Abreu et al. (18)
Fibrostenotic diseaseb
Ileal disease location Italian 133 Vavassori et al. (29)
Fibrostenotic diseasec
Fibrostenotic diseasec German 97 Radlmayer et al. (28)
Ileal disease location Italian 316 Annese et al. (37)
Fibrostenotic diseaseb
Fibrostenotic diseasec German 80 Seiderer et al. (53)
Ileal disease location German 303 Seiderer et al. (24)
Fibrostenotic diseasec
Ileal disease location Caucasian 1528 Cleynen et al. (50)
Fibrostenotic diseasea
Ileal disease location German 550 Schnitzler et al. (51)
Fibrostenotic diseasec
All SNPs combined Ileal disease location British 244 Ahmad et al. (19)
Fibrostenotic diseased
Ileal disease location Finnish 271 Heliö et al. (32)
Fibrostenotic diseasec
Ileal disease location Hungarian 527 Lakatos et al. (38)
Fibrostenotic diseasec
Ileal disease location North-American 201 Abreu et al. (18)
Fibrostenotic diseasea
Colonic disease location Caucasian 453 Lesage et al. (26)
Fibrostenotic diseasea
Ileal disease location North-American 275 Brant et al. (31)
Fibrostenotic diseasea
Ileal disease location Italian 316 Annese et al. (37)
Fibrostenotic diseasea
Ileal disease location Caucasian 1528 Cleynen et al. (50)
Fibrostenotic diseasea
Ileal disease location Spanish 239 Sabate et al. (52)
Fibrostenotic diseasec
If a significant association between the given variant and disease location is found in the reference, this is mentioned in the table.
aCorrected for disease location.
bUnclear if corrected for disease location.
cNot corrected for disease location.
dNo longer significant after multivariate analysis taking into account disease location.
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disease location is in part genetically determined, it is consid-
ered an intrinsic aspect of a patient’s clinical disease and the 
major driver to changes in disease behavior over time (15).
If there would be an independent association between NOD2 
variants and fibrostenotic disease in CD, how could this be 
pathophysiologically explained? NOD2 variants might induce 
fibrostenotic disease by shifting T lymphocytes toward tissue 
growth factor beta (TGF-β) cytokine production and by increas-
ing collagen deposition by smooth muscle cells and fibroblasts 
in the intestine (18). Of the three main variants, functional data 
are primarily available for Leu1007fsinC: Leu1007fsinC leads to 
a truncated CARD15 protein, resulting in an altered activation 
of NF-κB following bacterial triggers (23). Furthermore, it was 
previously thought that Leu1007fsinC was associated with an 
impaired IL-1β production and dendritic cell function, resulting 
in a dysregulation of the antibacterial host defense, increased 
intestinal permeability, and impaired regulation of innate and 
adaptive immunity in the intestinal tract (53). However, Maeda 
et al. later on reported Leu1007fsinC is associated with enhanced 
NF-κB activation and IL-1β secretion in mice (20). Additional 
mechanisms, such as diminished mucosal alpha-defensin expres-
sion, might also be involved (53). It is possible that the other 
two variants also alter the structure of LRR domain, resulting in 
abnormalities in bacterial recognition (35).
Autophagy-Related 16-Like 1
The ATG16L1 gene, member of a large family of genes involved 
in autophagocytosis, is located on chromosome 2q37. It encodes 
a protein in the autophagosome pathway that is essential in the 
targeting and destruction of pathogen-derived proteins in the 
innate immune response (54, 55). Furthermore, autophagy is 
important for degrading cytoplasmic components, sequestered 
within vesicles, by the lysosome (21).
After the ATG16L1 T300A variant (rs2241880) was identified 
as a susceptibility variant for CD (54, 56, 57), Prescott et al. were 
the first to associate this variant with ileal disease location, inde-
pendent of NOD2 state or disease duration; they did not mention 
an association with stricturing disease (55). Later on, Fowler et al. 
reported a significant association between fibrostenotic disease, 
the GG risk genotype, and ileal disease, independent of NOD2 
(although the number of NOD2 variants in their Australian CD 
population might be too small) (58). However, the European 
IBDchip Project could not confirm this association between 
ATG16L1 T300A and fibrostenotic disease (50).
The T300A amino acid substitution is a highly conserved 
residue that is located in the WD-repeat domain of autophagy-
related 16-like 1 (ATG16L1) and which may therefore affect 
interactions of the protein with other components of the 
autophagosome (55). This variant plays an important role in 
pathogen clearance (59), resulting in imbalanced cytokine 
production (60). Moreover, presence of this ATG16L1 risk allele 
seems associated with a reduced ability to generate a specific type 
of macrophages (Mφind, phenotypically closely resembling the 
anti-inflammatory CD206+ M2-macrophages), also implying 
an impaired anti-inflammatory functioning (61). The resulting 
inflammatory signals could eventually stimulate mesenchymal 
cells to make enormous amounts of collagen and other fibrogenic 
molecules (62). Importantly, a link between NOD2 and ATG16L1 
in the activation of autophagy could also be relevant for intestinal 
fibrogenesis: it is possible that NOD2 and/or ATG16L1 variants 
jointly can alter the responsiveness of immune cells to bacterial 
components, thereby amplifying inflammatory signals leading to 
fibrosis (62). Moreover, the ATG16L1 T300A variant enhances 
NOD2-driven cytokine production in an autophagy-independent 
manner (60, 63).
interleukin-23 Receptor
IL-23R is found on chromosome 1p31 and encodes a subunit of the 
receptor for the proinflammatory cytokine interleukin-23 (64). It 
is highly expressed on the cell membrane of memory T cells and 
other immune cells, such as natural killer cells, monocytes, and 
dendritic cells, which identify foreign substances to defend the 
body against infection. Interleukin-23 receptor (IL-23R) is involved 
in the mediation of proinflammatory activities by the production of 
interleukin 17 via the activation of Th17 lymphocytes (21).
After Duerr et al. described IL-23R as a susceptibility gene to 
CD (64), Glas et al. published a genotype–phenotype correlation 
for the rs1004819 SNP within IL-23R. This group noticed an 
increased incidence of ileal involvement and fibrostenotic disease 
in TT homozygous carriers compared to CC wild-type carriers, 
which, both however, lost significance after Bonferroni correc-
tion (65). We did not find evidence of an association of the main 
CD-associated SNP in IL-23R, rs11202926 (64), with intestinal 
fibrosis in existing literature.
Major Histocompatibility Complex
The major histocompatibility complex (MHC) region encodes a 
large number of immunological proteins, including the antigen-
presenting classical human leukocyte antigen (HLA) molecules. 
Genome-wide association studies of IBD have shown strong 
evidence of association with the MHC complex (66). Because of 
the complexity of the region, many researchers avoid including 
this region into their analysis. One study by Ahmad et al. studied 
340 SNPs in 24 genes from the HLA region in relation with 
fibrotic CD, but did not find an association (19). The IIBDGC 
genotype–phenotype study found a genome-wide significant 
association with rs77005575 located in the MHC region and 
disease behavior, independent of disease location (15). None of 
the included classical HLA alleles were independently associated 
with disease behavior in this study.
Toll-Like Receptors
Toll-like receptors (TLRs) are transmembrane domain protein 
with a tripartite structure: they contain an extracellular domain 
(including LRRs) responsible for ligand recognition, a single 
transmembrane-spanning region, and a globular cytoplasmic 
Toll/IL-1 receptor (TIR)-signaling domain. Currently, 10 TLRs 
are described in humans (67). They are expressed in myeloid 
cells and play a major role both in detecting microbes and in 
initiating innate immune responses. TLR4, expressed in the Golgi 
apparatus of intestinal epithelial cells (IECs), interacts with LPS, 
contributing to the perpetuation of inflammatory epithelial cell 
injury via tumor necrosis factor alpha (TNF-α)-induced altera-
tions of enterocyte turnover in an (auto)paracrine matter (38).
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In 2004, Franchimont et al. identified rs4986790 (Asp299Gly), 
within TLR4 as a susceptibility variant to CD, regardless of 
association with phenotype (68). This variant is associated with 
decreased responsiveness to endotoxins in humans (69, 70). 
Lakatos et  al. could not find this association in a Hungarian 
cohort (possibly because the variant allele is more present in 
their control population compared to Franchimont et  al.), and 
they also did not find a genotype–phenotype correlation for this 
SNP (38). Although there is no strong evidence for a role for 
TLR4 in the pathogenesis of fibrostenotic disease in CD, Rieder 
et al. suggested the first direct link between innate immunity to 
bacteria (via TLRs) and fibrosis in humans (71). Furthermore, in 
other diseases, such as systemic sclerosis and liver fibrosis, TLR4 
might have a pathophysiological contribution (72, 73).
Fractalkine Receptor 1, CX3CR1
CX3CR1 (previously termed V28) is a leukocyte chemotactic 
and adhesion receptor that binds fractalkine (CX3CL1 or 
neurotactin, expressed in epithelial and endothelial cells), a 
CX3C chemokine that exhibits properties of both traditional 
chemokines and adhesion molecules (74). CX3CR1 is expressed 
on natural killer cells, monocytes, CD8+, and some CD4+ 
T  cells. By binding fractalkine, it regulates the migration of a 
subpopulation of CD8+ intraepithelial lymphocytes into the 
intestinal lamina propria and their interaction with IECs (74). 
After stimulation by bacteria (or bacterial degradation prod-
ucts), CX3CR1-expressing cells rapidly adhere to the inflamed 
vascular endothelium and may play a role as a vascular gateway 
for cytotoxic effector cells (52).
After two strongly correlated (D′ = 0.99) CX3CR1 polymor-
phisms (V249I, rs3732379; T280M, rs3732378) were identified in 
HIV-positive patients (75), Brand et al. investigated these SNPs 
in the context of CD. They observed an association between both 
SNPs and fibrostenotic disease (without Bonferroni correction), 
but this was not independent of ileocolonic disease location (74). 
Later, Sabate et  al. again noticed a trend toward fibrostenotic 
behavior in V249I carriers (not statistically significant after 
Bonferroni correction), especially in smokers, independent 
of NOD2 Leu1007fsinC carriage and ileal involvement (52). 
Although the two SNPs are strongly correlated (75), Sabate et al. 
did not see a similar trend for T280M (52).
Several findings point toward CX3CR1 as a critical component 
in maintaining homeostasis of lamina propria macrophages, and 
master regulators of inflammation and fibrosis (76). Importantly, 
specifically for the described variants, it was shown in vitro that 
peripheral blood mononuclear cells (PBMCs) from individu-
als with wild-type CX3CR1 genotype adhere more potently to 
membrane-bound fractalkine than do PBMCs from homozygous 
V249I–T280M donors (74, 77). Despite the limited data about 
an association between CX3CR1 and fibrostenotic disease, these 
functional data could point toward a true role for the CX3CR1/
fractalkine axis in fibrosis in CD.
Tissue Growth Factor Beta
Tissue growth factor beta is encoded by a gene on chromo-
some 19q13. It is a regulatory protein that plays a key role in 
inflammatory, fibrotic, and immunological events in the intes-
tinal mucosa (78, 79). Enhanced expression of TGF-β and its 
receptors seems to be involved in the pathogenesis of CD, and 
might contribute to fibrosis (80, 81). After some SNPs (including 
C509T) in the TGF-β1-gene were described to lead to variations 
in the production of TGF-β serum levels in women (82, 83), some 
groups looked in vain for an association with susceptibility to CD 
(79, 81, 84). However, Hume et al. observed a significant associa-
tion between the AA genotype of a SNP in codon 25 in the TGF-
β1 gene and a fibrostenotic phenotype. CD patients homozygous 
for the profibrotic A allele also tended to have a shorter time to 
intestinal resection (79).
Angiotensinogen
Angiotensinogen, mapped to chromosome 1q42, is meant to 
function locally as a cytokine in several organ systems, participat-
ing in the regulation of inflammation and fibrosis. After being 
cleaved by renin into angiotensin I and processed to angiotensin 
II, it may increase the production of TGF-β1 (79).
After a gain of function SNP 6 bp from the transcription site 
was described in the angiotensinogen gene (85), Hume et al. stud-
ied its association with CD and CD phenotype. They reported a 
positive association for the A allele and CD, although without any 
genotype–phenotype association at the univariate or multivariate 
level (79).
Matrix Metalloproteinases and Tissue 
inhibitors of MMPs
Matrix metalloproteinases (MMPs), all Zn-activated endopro-
teinases, are subdivided into four groups, depending on their 
structure and substrate specificity: collagenases, gelatinases, 
stromelysins, and membrane-type MMPs (86–88). They mediate 
degradation of essentially all components of the extracellular 
matrix. The enzymatic activity of these potentially harmful pro-
teinases is tightly controlled and counterbalanced by endogenous 
inhibitors, such as alpha 2 macroglobulin, and specific tissue 
inhibitors of MMPs, the so-called TIMPs. TIMPs are produced 
by the same cell types that produce MMPs, primarily in cells 
resembling macrophages and fibroblasts (87, 89).
In the last decade, many different SNPs in these genes were 
described, related to processes such as fetal development (90), 
primary sclerosing cholangitis (91), and coronary atherosclerosis 
(92). Meijer et al. also studied their role in relation to CD suscep-
tibility and CD phenotype. They found that the 5T5T genotype at 
the MMP-3 locus (an additional thymidine insertion at −1613 of 
the MMP-3 promoter) was associated with fibrostenotic CD (88). 
Furthermore, expression data of Warnaar et  al. demonstrated 
increased levels of MMP-3 in stenotic and prestenotic resected 
CD ileum, pointing to an MMP-3 (stromelysin-1)-mediated 
altered clinical course of CD patients. These findings might 
explain the high recurrence rate of intestinal strictures, as in 
non-resected, prestenotic CD ileum in which the anastomosis 
is made, tissue turnover is present (89). Conflicting evidence 
exists regarding the consequences of the 5T5T genotype: some 
groups reported upregulation of MMP-3 expression (93, 94), 
whereas others reported a downregulation (95). In the study by 
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Meijer et  al., patients stratified according to MMP-3 genotype 
had similar MMP-3 total activity (88).
Membrane-Associated Guanylate Kinase, 
ww and PDZ Domain-Containing 1
MAGI1 is located on chromosome 3p14 and encodes the 
membrane-associated guanylate kinase WW and PDZ domain-
containing protein 1 (96). This protein plays an important role 
in the tight junction of IECs through interaction with JAM4, a 
junctional adhesion transmembrane molecule. Disruption of 
this epithelial barrier can have dramatic effect on the mucosal 
integrity, which has been shown to contribute to the development 
of CD (96).
Alonso et  al. recently published an interesting association 
between fibrostenotic CD and rs11924265, located in a 46.5-kb 
haplotype block inside a MAGI1 intron. They validated this 
association in an independent replication cohort (96). Previously, 
other groups have shown a significant increase in intestinal per-
meability in patients with stricturing disease (97). Rs11924265 
might induce an alteration in the membrane-associated guanylate 
kinase, WW and PDZ domain-containing 1 (MAGI1) protein 
function, contributing to an exaggerated immune response and 
to the subsequent transmural inflammation of the gastrointesti-
nal tract (96).
Janus Kinase 2
JAK2, located on chromosome 9, encodes for an intracellular 
tyrosine kinase that transduces cytokine-mediated signals 
via the JAK-STAT pathway (50, 70). The large, retrospective, 
and multicentre IBDchip study found that rs10758669 (C 
allele), within the JAK2 gene, is associated with an increased 
risk for ileal involvement and stenosing disease behavior. One 
mechanism by which Janus kinase 2 (JAK2) contributes to this 
fibrostenotic disease could be by altering intestinal permeability 
(50). Indeed, Prager et al. previously demonstrated that patients 
carrying the rs10758669 C risk allele significantly more often 
had an increased permeability compared with patients without 
the C allele (98).
Fucosyltransferase 2
FUT2, located on chromosome 19 (70), encodes the secretor 
enzyme alpha(1,2)-fucosyltransferase (Lewis blood group 
system), which allows expression of ABO antigens on the gastro-
intestinal mucosa and in bodily secretions (secretor phenotype) 
(99). After a nonsense allele in FUT2, rs601338 (W143X), was 
identified as a susceptibility variant for CD (100, 101), Forni et al. 
found non-secretors to be at slightly higher risk of a stricturing/
penetrating behavior (OR 1.51, p =  0.046). Additionally, their 
analysis revealed patients with blood group O are less likely to 
develop a stricturing disease (OR 0.70, p = 0.038) (99). Although 
it is known that fucosyltransferase 2 (FUT2) expression affects 
the composition of the gut microbiota (102), the pathophysi-
ological link between this specific SNP and fibrostenotic disease 
has not been unraveled yet. Theoretically, an altered microbial 
environment might induce more severe inflammation, leading to 
a more aggressive phenotype.
Other Genes
In 2009, Henckaerts et  al. examined the influence of some 
CD-associated susceptibility loci on changes in disease behavior. 
They found that homozygosity for the rs1363670 G-allele in a 
gene encoding a hypothetical protein near the IL12B gene, located 
on chromosome 5, was independently associated with stricturing 
disease behavior, especially in patients with ileal involvement 
(70, 103). So far, the pathophysiological consequences of this 
SNP, leading to a non-coding transcript variant, are not fully 
understood (70).
Because inherited risk factors [factor V Leiden, methylene-
tetrahydrofolate reductase (MTHFR) C677T] have been reported 
to be associated with fibrosis in other chronic inflammatory 
diseases, Novacek et al. performed a retrospective study in CD 
patients aiming to identify these risk factors in fibrostenotic 
CD. They concluded that the MTHFR 6777TT variant, factor V 
Leiden, and the prothrombin G20210A variant are not associated 
with fibrostenosis in CD (104).
As TNFα plays a pivotal role in the pathophysiology of 
IBD, confirmed by the efficacy of anti-TNF drugs, such as inf-
liximab and adalimumab (105), Meijer et al. investigated the 
association between a SNP (G308A) in TNFα and fibrostenotic 
disease (88). In line with other reports (106, 107), they could 
not find an association between this SNP and fibrostenotic 
CD (88).
The Combined Action of the Known 
Susceptibility variants
Crohn’s disease is a complex multigenic disease, where several 
small-effect risk variants combined influence disease onset. It is 
more and more suggested that combining the many individually 
weak signals into a genetic risk score might be a more powerful 
approach to study the genetic association with subphenotypes or 
to improve predictive ability of disease (15, 108). Such a genetic 
risk score was calculated in the IIBDGC genotype–phenotype 
study and tested for association with several disease subphe-
notypes. A strong association with disease behavior was found 
(p = 9.23 × 10−18), indicating that the known susceptibility loci 
combined can be a useful measurement of CD subtypes, but still 
do not have enough predictive ability to distinguish between the 
different subtypes (15).
GeNeTiCS AND FiBROSiS iN 
PeDiATRiC CD
Currently, not much is known about the genotype–phenotype 
association in pediatric CD. Russell et al. studied NOD2 variants 
in the Scottish early onset CD population (aged <16 years) and 
noticed a relatively small contribution to CD susceptibility, but 
a major impact on phenotype. Presence of stricturing disease 
behavior at diagnosis showed a trend toward an increase in 
carriers of NOD2 variant alleles, which became significant by 
2 years of follow-up (39). The association of NOD2 variants and 
fibrostenotic pediatric CD was previously already reported by 
two other groups (109, 110).
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In contrast with a study in adult CD (79), Liberek et al. could 
not find any significant correlation between the four common 
SNPs in TGF-β and any specific clinical parameter (111).
In 2014, Strisciuglio et al. performed a genotype–phenotype 
correlation study, focusing on autophagy gene variants. They 
observed a trend toward switching to a fibrostenotic disease in 
children homozygous for the ATG16L1 T300A risk allele. They 
did not find an association between NOD2 variants and strictur-
ing CD (112).
GeNeTiCS AND FiBROSiS AROUND 
THe wORLD
Although the incidence of IBD is rising in developing countries 
(113, 114), epidemiological data on the clinical phenotype of 
disease, and genotype–phenotype association studies, in non-
European populations are limited. Similar as for Caucasian 
populations though, several smaller genotype–phenotype studies 
have been performed in non-Caucasian populations (115–120). 
These usually study the same variants as those considered in 
Caucasian populations (NOD2, IL-23R, etc.), but only one Korean 
study found the IL23R variant rs1004819 associated with strictur-
ing and penetrating disease (119). It is possibly not surprising 
that NOD2 variants are not found to be associated with disease 
(subtypes) in different populations, as NOD2 variants have 
been seen with different frequencies in geographically diverse 
populations. Whereas the prevalence of CD patients who carry 
at least one NOD2 susceptibility variant varies from 27 to 50% 
in most Caucasian European populations, observed frequencies 
are much lower (15–21%) in Scandinavian countries (121, 122), 
which are generally characterized by more homogenous study 
populations. Caucasian populations, relatively far from Europe, 
but with European ancestry with hardly no racial mixing, such 
as the United States, Canada, and Australia, have NOD2 vari-
ant frequencies comparable with those found across the rest of 
Europe (122). In Asians (Japanese, Chinese, and Korean), Arabs, 
Africans, and African-Americans, the NOD2 variants are rare or 
even absent (5, 21, 116).
Recently, the first trans-ancestry association study of IBD was 
published by the IIBDGC (5). They collected subphenotype data 
on 1991 patients with CD from East Asia, India, and Iran, and 
compared these data with available clinical phenotypes for 19,290 
Europeans (15). They showed some demographic differences, 
with, for example, more stricturing behavior and perianal and less 
inflammatory CD in the non-European population compared to 
the European population, in line with the previously reported 
prospectively collected clinical findings in incident cases of IBD 
in non-Europeans (114). It will be interesting to see if these 
differences are explained by genetic factors that differ between 
populations, or rather by environmental factors (including differ-
ent health-care systems), ascertainment bias, or a combination of 
these. The trans-ancestry association study showed that although 
for the majority of the IBD risk loci, the direction and magnitude 
of effect are consistent in European and non-European cohorts, 
genetic heterogeneity was seen between divergent populations 
at several established risk loci, driven by differences in allele 
frequency (NOD2), effect size (TNFSF15 and ATG16L1), or a 
combination of both (IL23R and IRGM). A large trans-ancestry 
genotype–phenotype study is under way, undoubtedly shedding 
light on possible genetic heterogeneity of disease subphenotypes 
in different populations.
THe PROMiSe OF ePiGeNeTiCS
So far, the epigenetic control of inflammation and fibrosis in IBD 
is not fully understood (12). But, as only a modest fraction (ca. 
15%) of the 200 association signals is driven by missense muta-
tions, the large majority of causal alleles is likely to be related 
to regulatory functions such as modulation of gene expression 
(123). Intestinal disease-associated DNA methylations in IBD 
do occur, leading to changes in gene expression (124), such as 
in several loci within the interleukin 12/interleukin 23 pathway 
(125). As epigenetic changes are dynamically responsive to the 
environment, they are likely to play a key role in the pathogenesis 
of fibrosis and offer a molecular explanation for how the intestine 
becomes profibrotic (126).
Sadler et al. recently published their genome-wide analysis of 
DNA methylation and gene expression in the context of fibrotic 
CD (126). They found three functional candidate genes to be 
differentially methylated and expressed in fibrotic CD: wingless-
type mouse mammary tumor virus integration site family 
member 2B (WNT2B), prostacyclin synthase (PTGIS), and pros-
taglandin D2 synthase (PTGDS) (126). The decreased expression 
of hypermethylated WNT2B and PTGIS are novel findings both 
in the context of fibrosis and CD, though hypermethylation of 
the PTGIS promoter has been described as a feature of colorectal 
cancer (127). Interestingly, increased expression of WNT2B has 
been detected in the intestinal mucosa of UC patients (128), 
suggesting that WNT2B may perform distinct functions in CD 
and UC (126). Hypomethylation of the PTGDS gene, together 
with increased gene expression levels, was previously noticed 
in a murine UC model (129). In future, both epigenetic and 
transcriptomic analyses will undoubtedly reveal novel insights 
in the pathogenesis of stricturing CD, potentially leading to new 
targeted therapies.
CLiNiCAL iMPLiCATiONS
Based on current evidence, it is too early to adjust treatment in 
CD patients according to genetic profiles, in order to personalize 
treatment in CD (15). NOD2 is by far the most studied genetic pre-
dictor for fibrostenotic disease in CD, and many studies suggested 
an important role for NOD2 variants in developing fibrostenotic 
CD. Still, the low sensitivity of a single NOD2 variant for predict-
ing fibrostenotic disease does not justify NOD2 genotyping in all 
patients (48), and there is no adequate scientific evidence for a 
top-down medical therapy based solely on NOD2 variants. It has 
been suggested that targeted early-intensive therapy for high-risk 
patients with two NOD2 mutations might be beneficial, if proven 
by prospective trials (47), but so far this evidence does not exist. 
Importantly, based on the biggest genotype–phenotype study 
ever done including over 19,000 CD patients, it was found that 
no NOD2 variants are associated with fibrostenotic disease after 
conditioning for disease location. Disease location thus seems to 
FiGURe 1 | Overview of different interacting aspects important in fibrotic CD pathogenesis. In each of the four main categories, we indicate some factors 
for which a role in fibrotic CD has been shown, with an emphasis on the genetic factors reviewed in this paper. Pointed and barred arrows denote a positive and 
negative interaction, respectively.
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be the major driver to changes in disease behavior over time (15). 
Preferential involvement of the terminal ileum could be explained 
by NOD2 variants abrogating normal Paneth cell behavior, as 
Paneth cells express NOD2/CARD15 throughout the small intes-
tine, with maximal expression in the terminal ileum (35, 130).
CONCLUSiON AND FUTURe DiReCTiONS
As outlined above, several genotype–phenotype studies have 
been performed to find which genetic variants play a role in 
defining CD disease location and behavior, but hardly any 
variants were uniformly found as independent risk factors for 
developing fibrostenotic disease in CD. Different reasons can be 
put forward. The first one is related to power of the individual 
studies. Many studies indeed included relatively small patient 
numbers (Table  1), and looking into subgroups of patients 
makes the sample sizes even smaller. It should also be noted 
that various studies might include patient groups from either 
population-based registries and/or from secondary or tertiary 
referral centers. This has a direct influence on the proportion of 
patients with more severe disease as opposed to inflammatory 
disease, which in turn could lead to over or under presentation 
of certain genetic associations. An example is the Scandinavian 
registries that are population-based and where indeed a lower 
proportion of stenosing and penetrating CD is seen (15). NOD2 
frequencies in these populations are also lower (see above) (121), 
but this could be linked to the population-based character of 
the study population. Third, most susceptibility variants are not 
the pathophysiological causal ones, but are in LD with the true 
causal variant(s) at that locus, which might have more qualitative 
9Verstockt and Cleynen Genetics in Fibrostenotic Crohn’s Disease
Frontiers in Medicine | www.frontiersin.org May 2016 | Volume 3 | Article 24
ReFeReNCeS
1. Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, et al. Long-term 
evolution of disease behavior of Crohn’s disease. Inflamm Bowel Dis (2002) 
8(4):244–50. doi:10.1097/00054725-200207000-00002 
2. Louis E, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi FA, Belaiche 
J. Behaviour of Crohn’s disease according to the Vienna classification: 
changing pattern over the course of the disease. Gut (2001) 49(6):777–82. 
doi:10.1136/gut.49.6.777 
3. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel 
disease. Nature (2007) 448(7152):427–34. doi:10.1038/nature06005 
4. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, et al. Host-
microbe interactions have shaped the genetic architecture of inflammatory 
bowel disease. Nature (2012) 491(7422):119–24. doi:10.1038/nature11582 
5. Liu JZ, van Sommeren S, Huang H, Ng SC, Alberts R, Takahashi A, et al. 
Association analyses identify 38 susceptibility loci for inflammatory bowel 
disease and highlight shared genetic risk across populations. Nat Genet 
(2015) 47:979–86. doi:10.1038/ng.3359 
6. Van Assche G, Geboes K, Rutgeerts P. Medical therapy for 
Crohn’s disease strictures. Inflamm Bowel Dis (2004) 10(1):55–60. 
doi:10.1097/00054725-200401000-00009 
7. Rieder F, Zimmermann EM, Remzi FH, Sandborn WJ. Crohn’s disease 
complicated by strictures: a systematic review. Gut (2013) 62(7):1072–84. 
doi:10.1136/gutjnl-2012-304353 
8. Greenstein AJ, Zhang LP, Miller AT, Yung E, Branco BC, Sachar DB, et al. 
Relationship of the number of Crohn’s strictures and strictureplasties to post-
operative recurrence. J Am Coll Surg (2009) 208(6):1065–70. doi:10.1016/j.
jamcollsurg.2009.01.039 
9. Li C, Kuemmerle JF. Mechanisms that mediate the development of fibrosis 
in patients with Crohn’s disease. Inflamm Bowel Dis (2014) 20(7):1250–8. 
doi:10.1097/MIB.0000000000000043 
10. Speca S, Giusti I, Rieder F, Latella G. Cellular and molecular mechanisms of 
intestinal fibrosis. World J Gastroenterol (2012) 18(28):3635–61. doi:10.3748/
wjg.v18.i28.3635 
11. Wynn TA, Barron L. Macrophages: master regulators of inflammation and 
fibrosis. Semin Liver Dis (2010) 30(3):245–57. doi:10.1055/s-0030-1255354 
12. Latella G, Rogler G, Bamias G, Breynaert C, Florholmen J, Pellino G, et al. 
Results of the 4th scientific workshop of the ECCO (I): pathophysiology of 
intestinal fibrosis in IBD. J Crohns Colitis (2014) 8(10):1147–65. doi:10.1016/j.
crohns.2014.03.008 
13. Latella G, Di Gregorio J, Flati V, Rieder F, Lawrance IC. Mechanisms 
of initiation and progression of intestinal fibrosis in IBD. Scand 
or quantitative effects and explain the association with a certain 
clinical feature. Fourth, many studies apply different definitions 
for stenosing disease or use a limited number of variables given 
in the Vienna Classification (41). Another reason could be the 
dramatic change in disease behavior over the course of the 
disease, implying disease behavior of CD cannot be analyzed 
without taking into account the duration of disease (2, 30). Also, 
because of the importance of disease location in driving changes 
of disease behavior over time (15), disease location should 
always be considered when analyzing risk factors for stenosing 
disease. In the case of, for example, NOD2, there is a strong cor-
relation of NOD2 and ileal disease location (131), which might 
induce a false, confounded association between NOD2 variants 
and fibrostenotic disease in those cases where disease location 
is not considered in the genotype–phenotype analysis. Finally, 
disease behavior is influenced by environmental factors (132), 
which can be dramatically different in the different studies. 
Examples not only include smoking and NSAIDS use but also 
specific treatments may hide patients at risk to develop certain 
subtypes of disease. Any disease behavior and severity analysis 
should be interpreted with caution, when there is no access 
to medication use and response to medications, especially for 
patients in the biologics era.
Among the 163 genome-wide significant IBD susceptibility 
loci as identified in the study by Jostins et al. (4), genetic variants 
in immune system components (NOD2, IL-23R, IL-12B, JAK2, 
and FUT2) and autophagy [ATG16L1, leucine-rich repeat 
kinase 2 (LRRK2)] could (jointly) contribute to the activation 
of mesenchymal cells and pathogenesis of fibrosis (4, 9, 133). 
Although these susceptibility genes might pathophysiologically 
contribute to fibrostenotic processes, not all have been found 
to be associated with stricturing CD. For example, the LRRK2 
CD-associated M2397 allele inhibits nuclear factor of activated 
T cells (NFAT) (134), which is known to control fibroblast 
plasticity in the heart (135). LRRK2 might thus also be involved 
in fibrosis in the gut, although so far this has not been reported. 
We did not find any studies where a genetic association was 
shown between LRRK2 and fibrostenotic CD. The IIBDGC 
study by Cleynen et  al. in addition found that while many of 
the known 163 risk loci showed nominal evidence of associa-
tion with CD behavior, a combined genetic risk score of these 
individual weak signals was strongly associated with CD disease 
behavior (15). Still, the development of fibrosis is preceded by 
a period of initial inflammation, and not all patients with CD 
express a fibrostenotic phenotype (1, 2, 6). This highlights the 
possible difference between loci predisposing to overall disease 
(CD or UC) and loci predisposing to clinical phenotypes (4, 9, 
136). It is thus important to consider the idea of different genes 
driving susceptibility on the one hand and disease behavior on 
the other. The IIBDGC study for the first time does this on a 
large scale, but hardly finds any genome-wide significant loci for 
disease behavior independent from disease location, except from 
rs77005575 (MHC) (15).
Figure  1 gives an overview of different interacting aspects 
we believe are important in fibrotic CD pathogenesis and sum-
marizes the genetic factors identified thus far. In future studies 
aimed at finding the genetic contributions to fibrotic CD, it will 
be important to consider as much as possible environmental risk 
factors (smoking, diet, microbiota, medication use, etc.), as well 
as non-Caucasian populations. To gain additional insights into 
the pathophysiology of fibrotic CD, and find predictive markers, 
an integrated analysis, including genetics, epigenetics, transcrip-
tomics, microbiomics, etc., and prospective study setups, will be 
the next steps.
AUTHOR CONTRiBUTiONS
BV: literature search and drafting of the manuscript. IC: drafting 
of the manuscript and critical revision of the manuscript.
FUNDiNG
BV is a doctoral fellow funded by the Research Foundation 
Flanders, Belgium.
10
Verstockt and Cleynen Genetics in Fibrostenotic Crohn’s Disease
Frontiers in Medicine | www.frontiersin.org May 2016 | Volume 3 | Article 24
J Gastroenterol (2015) 50(1):53–65. doi:10.3109/00365521.2014. 
968863 
14. Chang CW, Wong JM, Tung CC, Shih IL, Wang HY, Wei SC. Intestinal 
stricture in Crohn’s disease. Intestinal Res (2015) 13(1):19–26. doi:10.5217/
ir.2015.13.1.19 
15. Cleynen I, Boucher G, Jostins L, Schumm LP, Zeissig S, Ahmad T, et  al. 
Inherited determinants of Crohn’s disease and ulcerative colitis phenotypes: 
a genetic association study. Lancet (2016) 387(10014):156–67. doi:10.1016/
S0140-6736(15)00465-1 
16. Ogura Y, Inohara N, Benito A, Chen FF, Yamaoka S, Nunez G. Nod2, a 
Nod1/Apaf-1 family member that is restricted to monocytes and activates 
NF-kappaB. J Biol Chem (2001) 276(7):4812–8. doi:10.1074/jbc.M008072200 
17. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, et al. 
Association of NOD2 leucine-rich repeat variants with susceptibility to 
Crohn’s disease. Nature (2001) 411(6837):599–603. doi:10.1038/35079107 
18. Abreu MT, Taylor KD, Lin YC, Hang T, Gaiennie J, Landers CJ, et al. Mutations 
in NOD2 are associated with fibrostenosing disease in patients with Crohn’s 
disease. Gastroenterology (2002) 123(3):679–88. doi:10.1053/gast.2002.35393 
19. Ahmad T, Armuzzi A, Bunce M, Mulcahy-Hawes K, Marshall SE, Orchard 
TR, et al. The molecular classification of the clinical manifestations of Crohn’s 
disease. Gastroenterology (2002) 122(4):854–66. doi:10.1053/gast.2002.32413 
20. Maeda S, Hsu LC, Liu H, Bankston LA, Iimura M, Kagnoff MF, et al. Nod2 
mutation in Crohn’s disease potentiates NF-kappaB activity and IL-1beta 
processing. Science (2005) 307(5710):734–8. doi:10.1126/science.1103685 
21. Naser SA, Arce M, Khaja A, Fernandez M, Naser N, Elwasila S, et al. Role 
of ATG16L, NOD2 and IL23R in Crohn’s disease pathogenesis. World 
J Gastroenterol (2012) 18(5):412–24. doi:10.3748/wjg.v18.i5.412 
22. Hampe J, Cuthbert A, Croucher PJ, Mirza MM, Mascheretti S, Fisher S, 
et  al. Association between insertion mutation in NOD2 gene and Crohn’s 
disease in German and British populations. Lancet (2001) 357(9272):1925–8. 
doi:10.1016/S0140-6736(00)05063-7 
23. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, et  al. A 
frameshift mutation in NOD2 associated with susceptibility to Crohn’s 
disease. Nature (2001) 411(6837):603–6. doi:10.1038/35079114 
24. Seiderer J, Schnitzler F, Brand S, Staudinger T, Pfennig S, Herrmann K, et al. 
Homozygosity for the CARD15 frameshift mutation 1007fs is predictive of 
early onset of Crohn’s disease with ileal stenosis, entero-enteral fistulas, and 
frequent need for surgical intervention with high risk of re-stenosis. Scand 
J Gastroenterol (2006) 41(12):1421–32. doi:10.1080/00365520600703900 
25. Cuthbert AP, Fisher SA, Mirza MM, King K, Hampe J, Croucher PJ, et al. 
The contribution of NOD2 gene mutations to the risk and site of disease 
in inflammatory bowel disease. Gastroenterology (2002) 122(4):867–74. 
doi:10.1053/gast.2002.32415 
26. Lesage S, Zouali H, Cézard JP, Colombel JF, Belaiche J, Almer S, et  al. 
CARD15/NOD2 mutational analysis and genotype-phenotype correlation 
in 612 patients with inflammatory bowel disease. Am J Hum Genet (2002) 
70(4):845–57. doi:10.1086/339432 
27. Hampe J, Grebe J, Nikolaus S, Solberg C, Croucher PJ, Mascheretti S, et al. 
Association of NOD2 (CARD 15) genotype with clinical course of Crohn’s 
disease: a cohort study. Lancet (2002) 359(9318):1661–5. doi:10.1016/
S0140-6736(02)08590-2 
28. Radlmayr M, Török HP, Martin K, Folwaczny C. The c-insertion mutation 
of the NOD2 gene is associated with fistulizing and fibrostenotic phenotypes 
in Crohn’s disease. Gastroenterology (2002) 122(7):2091–2. doi:10.1053/
gast.2002.34020 
29. Vavassori P, Borgiani P, D’Apice MR, De Negris F, Del Vecchio Blanco G, 
Monteleone I, et al. 3020insC mutation within the NOD2 gene in Crohn’s 
disease: frequency and association with clinical pattern in an Italian popu-
lation. Dig Liver Dis (2002) 34(2):153. doi:10.1016/S1590-8658(02)80249-3 
30. Louis E, Michel V, Hugot JP, Reenaers C, Fontaine F, Delforge M, et al. Early 
development of stricturing or penetrating pattern in Crohn’s disease is influ-
enced by disease location, number of flares, and smoking but not by NOD2/
CARD15 genotype. Gut (2003) 52(4):552–7. doi:10.1136/gut.52.4.552 
31. Brant SR, Picco MF, Achkar JP, Bayless TM, Kane SV, Brzezinski A, et  al. 
Defining complex contributions of NOD2/CARD15 gene mutations, age at 
onset, and tobacco use on Crohn’s disease phenotypes. Inflamm Bowel Dis 
(2003) 9(5):281–9. doi:10.1097/00054725-200309000-00001 
32. Heliö T, Halme L, Lappalainen M, Fodstad H, Paavola-Sakki P, Turunen U, 
et  al. CARD15/NOD2 gene variants are associated with familially occur-
ring and complicated forms of Crohn’s disease. Gut (2003) 52(4):558–62. 
doi:10.1136/gut.52.4.558 
33. Mendoza JL, Murillo LS, Fernández L, Peña AS, Lana R, Urcelay E, et  al. 
Prevalence of mutations of the NOD2/CARD15 gene and relation to phe-
notype in Spanish patients with Crohn disease. Scand J Gastroenterol (2003) 
38(12):1235–40. doi:10.1080/00365520310006612 
34. Heresbach D, Gicquel-Douabin V, Birebent B, D’halluin PN, Heresbach-Le 
Berre N, Dreano S, et al. NOD2/CARD15 gene polymorphisms in Crohn’s 
disease: a genotype-phenotype analysis. Eur J Gastroenterol Hepatol (2004) 
16(1):55–62. doi:10.1097/00042737-200401000-00009 
35. Economou M, Trikalinos TA, Loizou KT, Tsianos EV, Ioannidis JP. Differential 
effects of NOD2 variants on Crohn’s disease risk and phenotype in diverse 
populations: a metaanalysis. Am J Gastroenterol (2004) 99(12):2393–404. 
doi:10.1111/j.1572-0241.2004.40304.x 
36. Alvarez-Lobos M, Arostegui JI, Sans M, Tassies D, Plaza S, Delgado S, et al. 
Crohn’s disease patients carrying Nod2/CARD15 gene variants have an 
increased and early need for first surgery due to stricturing disease and higher 
rate of surgical recurrence. Ann Surg (2005) 242(5):693–700. doi:10.1097/01.
sla.0000186173.14696.ea 
37. Annese V, Lombardi G, Perri F, D’Incà R, Ardizzone S, Riegler G, et  al. 
Variants of CARD15 are associated with an aggressive clinical course of 
Crohn’s disease – an IG-IBD study. Am J Gastroenterol (2005) 100(1):84–92. 
doi:10.1111/j.1572-0241.2005.40705.x 
38. Lakatos PL, Lakatos L, Szalay F, Willheim-Polli C, Osterreicher C, 
Tulassay Z, et  al. Toll-like receptor 4 and NOD2/CARD15 mutations in 
Hungarian patients with Crohn’s disease: phenotype-genotype correla-
tions. World J Gastroenterol (2005) 11(10):1489–95. doi:10.3748/wjg.v11. 
i10.1489 
39. Russell RK, Drummond HE, Nimmo EE, Anderson N, Smith L, Wilson 
DC, et al. Genotype-phenotype analysis in childhood-onset Crohn’s disease: 
NOD2/CARD15 variants consistently predict phenotypic characteristics of 
severe disease. Inflamm Bowel Dis (2005) 11(11):955–64. doi:10.1097/01.
MIB.0000183423.38037.f3 
40. Schnitzler F, Brand S, Staudinger T, Pfennig S, Hofbauer K, Seiderer J, 
et  al. Eight novel CARD15 variants detected by DNA sequence analysis 
of the CARD15 gene in 111 patients with inflammatory bowel disease. 
Immunogenetics (2006) 58(2–3):99–106. doi:10.1007/s00251-005-0073-2 
41. Oostenbrug LE, Nolte IM, Oosterom E, van der Steege G, te Meerman GJ, van 
Dullemen HM, et al. CARD15 in inflammatory bowel disease and Crohn’s 
disease phenotypes: an association study and pooled analysis. Dig Liver Dis 
(2006) 38(11):834–45. doi:10.1016/j.dld.2006.06.042 
42. Baptista ML, Amarante H, Picheth G, Sdepanian VL, Peterson N, 
Babasukumar U, et  al. CARD15 and IL23R influences Crohn’s disease 
susceptibility but not disease phenotype in a Brazilian population. Inflamm 
Bowel Dis (2008) 14(5):674–9. doi:10.1002/ibd.20372 
43. Glas J, Seiderer J, Tillack C, Pfennig S, Beigel F, Jürgens M, et al. The NOD2 
single nucleotide polymorphisms rs2066843 and rs2076756 are novel and 
common Crohn’s disease susceptibility gene variants. PLoS One (2010) 
5(12):e14466. doi:10.1371/journal.pone.0014466 
44. Jürgens M, Brand S, Laubender RP, Seiderer J, Glas J, Wetzke M, et al. The 
presence of fistulas and NOD2 homozygosity strongly predict intestinal ste-
nosis in Crohn’s disease independent of the IL23R genotype. J Gastroenterol 
(2010) 45(7):721–31. doi:10.1007/s00535-010-0231-7 
45. Ippoliti A, Devlin S, Mei L, Yang H, Papadakis KA, Vasiliauskas EA, et al. 
Combination of innate and adaptive immune alterations increased the 
likelihood of fibrostenosis in Crohn’s disease. Inflamm Bowel Dis (2010) 
16(8):1279–85. doi:10.1002/ibd.21196 
46. Rieder F, Lawrance IC, Leite A, Sans M. Predictors of fibrostenotic Crohn’s 
disease. Inflamm Bowel Dis (2011) 17(9):2000–7. doi:10.1002/ibd.21627 
47. Adler J, Rangwalla SC, Dwamena BA, Higgins PD. The prognostic power of 
the NOD2 genotype for complicated Crohn’s disease: a meta-analysis. Am 
J Gastroenterol (2011) 106(4):699–712. doi:10.1038/ajg.2011.19 
48. Brand S. Homozygosity for the NOD2 p.Leu1007fsX1008 variant is the main 
genetic predictor for fibrostenotic Crohn’s disease. Inflamm Bowel Dis (2012) 
18(2):393–4. doi:10.1002/ibd.21914 
11
Verstockt and Cleynen Genetics in Fibrostenotic Crohn’s Disease
Frontiers in Medicine | www.frontiersin.org May 2016 | Volume 3 | Article 24
49. Brand S. Moving the genetics of inflammatory bowel diseases from bench to 
bedside: first steps towards personalised medicine. Gut (2013) 62(11):1531–3. 
doi:10.1136/gutjnl-2012-304151 
50. Cleynen I, González JR, Figueroa C, Franke A, McGovern D, Bortlík M, et al. 
Genetic factors conferring an increased susceptibility to develop Crohn’s 
disease also influence disease phenotype: results from the IBDchip European 
Project. Gut (2013) 62(11):1556–65. doi:10.1136/gutjnl-2011-300777 
51. Schnitzler F, Friedrich M, Wolf C, Angelberger M, Diegelmann J, Olszak 
T, et  al. The NOD2 p.Leu1007fsX1008 mutation (rs2066847) is a stronger 
predictor of the clinical course of Crohn’s disease than the FOXO3A intron 
variant rs12212067. PLoS One (2014) 9(11):e108503. doi:10.1371/journal.
pone.0108503 
52. Sabate JM, Ameziane N, Lamoril J, Jouet P, Farmachidi JP, Soulé JC, et al. The 
V249I polymorphism of the CX3CR1 gene is associated with fibrostenotic 
disease behavior in patients with Crohn’s disease. Eur J Gastroenterol Hepatol 
(2008) 20(8):748–55. doi:10.1097/MEG.0b013e3282f824c9 
53. Seiderer J, Brand S, Herrmann KA, Schnitzler F, Hatz R, Crispin A, et  al. 
Predictive value of the CARD15 variant 1007fs for the diagnosis of intestinal 
stenoses and the need for surgery in Crohn’s disease in clinical practice: 
results of a prospective study. Inflamm Bowel Dis (2006) 12(12):1114–21. 
doi:10.1097/01.mib.0000235836.32176.5e 
54. Hampe J, Franke A, Rosenstiel P, Till A, Teuber M, Huse K, et al. A genome-
wide association scan of nonsynonymous SNPs identifies a susceptibility 
variant for Crohn disease in ATG16L1. Nat Genet (2007) 39(2):207–11. 
doi:10.1038/ng1954 
55. Prescott NJ, Fisher SA, Franke A, Hampe J, Onnie CM, Soars D, et  al. A 
nonsynonymous SNP in ATG16L1 predisposes to ileal Crohn’s disease and is 
independent of CARD15 and IBD5. Gastroenterology (2007) 132(5):1665–71. 
doi:10.1053/j.gastro.2007.03.034 
56. Rioux JD, Xavier RJ, Taylor KD, Silverberg MS, Goyette P, Huett A, et  al. 
Genome-wide association study identifies new susceptibility loci for Crohn 
disease and implicates autophagy in disease pathogenesis. Nat Genet (2007) 
39(5):596–604. doi:10.1038/ng2032 
57. Cummings JR, Cooney R, Pathan S, Anderson CA, Barrett JC, Beckly J, et al. 
Confirmation of the role of ATG16L1 as a Crohn’s disease susceptibility gene. 
Inflamm Bowel Dis (2007) 13(8):941–6. doi:10.1002/ibd.20162 
58. Fowler EV, Doecke J, Simms LA, Zhao ZZ, Webb PM, Hayward NK, 
et  al. ATG16L1 T300A shows strong associations with disease subgroups 
in a large Australian IBD population: further support for significant 
disease heterogeneity. Am J Gastroenterol (2008) 103(10):2519–26. 
doi:10.1111/j.1572-0241.2008.02023.x 
59. Begun J, Lassen KG, Jijon HB, Baxt LA, Goel G, Heath RJ, et al. Integrated 
genomics of Crohn’s disease risk variant identifies a role for CLEC12A in 
antibacterial autophagy. Cell Rep (2015) 11(12):1905–18. doi:10.1016/j.
celrep.2015.05.045 
60. Salem M, Ammitzboell M, Nys K, Seidelin JB, Nielsen OH. ATG16L1: a 
multifunctional susceptibility factor in Crohn disease. Autophagy (2015) 
11(4):585–94. doi:10.1080/15548627.2015.1017187 
61. Levin AD, Koelink PJ, Bloemendaal FM, Vos AC, D’Haens GR, van den Brink 
GR, et al. Autophagy contributes to the induction of anti-TNF induced mac-
rophages. J Crohns Colitis (2016) 10(3):323–9. doi:10.1093/ecco-jcc/jjv174 
62. Zorzi F, Calabrese E, Monteleone G. Pathogenic aspects and therapeutic 
avenues of intestinal fibrosis in Crohn’s disease. Clin Sci (Lond) (2015) 
129(12):1107–13. doi:10.1042/CS20150472 
63. Sorbara MT, Ellison LK, Ramjeet M, Travassos LH, Jones NL, Girardin SE, 
et  al. The protein ATG16L1 suppresses inflammatory cytokines induced 
by the intracellular sensors Nod1 and Nod2 in an autophagy-independent 
manner. Immunity (2013) 39(5):858–73. doi:10.1016/j.immuni.2013.10.013 
64. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, et al. A 
genome-wide association study identifies IL23R as an inflammatory bowel 
disease gene. Science (2006) 314(5804):1461–3. doi:10.1126/science.1135245 
65. Glas J, Seiderer J, Wetzke M, Konrad A, Török HP, Schmechel S, et  al. 
rs1004819 is the main disease-associated IL23R variant in German Crohn’s 
disease patients: combined analysis of IL23R, CARD15, and OCTN1/2 
variants. PLoS One (2007) 2(9):e819. doi:10.1371/journal.pone.0000819 
66. Goyette P, Boucher G, Mallon D, Ellinghaus E, Jostins L, Huang H, et al. High-
density mapping of the MHC identifies a shared role for HLA-DRB1*01:03 
in inflammatory bowel diseases and heterozygous advantage in ulcerative 
colitis. Nat Genet (2015) 47:172–9. doi:10.1038/ng.3176 
67. De Nardo D. Toll-like receptors: activation, signalling and transcriptional 
modulation. Cytokine (2015) 74(2):181–9. doi:10.1016/j.cyto.2015.02.025 
68. Franchimont D, Vermeire S, El Housni H, Pierik M, Van Steen K, Gustot 
T, et al. Deficient host-bacteria interactions in inflammatory bowel disease? 
The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with 
Crohn’s disease and ulcerative colitis. Gut (2004) 53(7):987–92. doi:10.1136/
gut.2003.030205 
69. Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M, et al. TLR4 
mutations are associated with endotoxin hyporesponsiveness in humans. Nat 
Genet (2000) 25(2):187–91. doi:10.1038/76048 
70. Yates A, Akanni W, Amode MR, Barrell D, Billis K, Carvalho-Silva D, et al. 
Ensembl 2016. Nucleic Acids Res (2016) 44(D1):D710–6. doi:10.1093/nar/
gkv1157 
71. Rieder F, Schirbel A, Ouyang Z, West G, Rho H, de la Motte C, et  al. 
Pro-fibrogenic activity of Toll-like receptor (TLR) and NOD-like receptor 
(NLR) ligands on human intestinal myofibroblasts (HIF) – linking bacterial 
innate immunity to intestinal fibrosis. Gastroenterology (2010) 38(5):S35. 
doi:10.1016/S0016-5085(10)60163-1 
72. Bhattacharyya S, Varga J. Emerging roles of innate immune signaling and 
toll-like receptors in fibrosis and systemic sclerosis. Curr Rheumatol Rep 
(2015) 17(1):474. doi:10.1007/s11926-014-0474-z 
73. Petrasek J, Csak T, Szabo G. Toll-like receptors in liver disease. Adv Clin Chem 
(2013) 59:155–201. doi:10.1016/B978-0-12-405211-6.00006-1 
74. Brand S, Hofbauer K, Dambacher J, Schnitzler F, Staudinger T, Pfennig S, 
et al. Increased expression of the chemokine fractalkine in Crohn’s disease 
and association of the fractalkine receptor T280M polymorphism with a 
fibrostenosing disease Phenotype. Am J Gastroenterol (2006) 101(1):99–106. 
doi:10.1111/j.1572-0241.2005.00361.x 
75. Faure S, Meyer L, Costagliola D, Vaneensberghe C, Genin E, Autran B, et al. 
Rapid progression to AIDS in HIV+ individuals with a structural variant 
of the chemokine receptor CX3CR1. Science (2000) 287(5461):2274–7. 
doi:10.1126/science.287.5461.2274 
76. Medina-Contreras O, Geem D, Laur O, Williams IR, Lira SA, Nusrat A, 
et  al. CX3CR1 regulates intestinal macrophage homeostasis, bacterial 
translocation, and colitogenic Th17 responses in mice. J Clin Invest (2011) 
121(12):4787–95. doi:10.1172/JCI59150 
77. Daoudi M, Lavergne E, Garin A, Tarantino N, Debré P, Pincet F, et al. Enhanced 
adhesive capacities of the naturally occurring Ile249-Met280 variant of 
the chemokine receptor CX3CR1. J Biol Chem (2004) 279(19):19649–57. 
doi:10.1074/jbc.M313457200 
78. Schulte CM, Dignass AU, Goebell H, Röher HD, Schulte KM. Genetic factors 
determine extent of bone loss in inflammatory bowel disease. Gastroenterology 
(2000) 119(4):909–20. doi:10.1053/gast.2000.18158 
79. Hume GE, Fowler EV, Lincoln D, Eri R, Templeton D, Florin TH, et  al. 
Angiotensinogen and transforming growth factor beta1: novel genes in the 
pathogenesis of Crohn’s disease. J Med Genet (2006) 43(10):e51. doi:10.1136/
jmg.2005.040477 
80. di Mola FF, Friess H, Scheuren A, Di Sebastiano P, Graber H, Egger B, 
et  al. Transforming growth factor-betas and their signaling receptors 
are coexpressed in Crohn’s disease. Ann Surg (1999) 229(1):67–75. 
doi:10.1097/00000658-199901000-00009 
81. Schulte CM, Goebell H, Röher HD, Schulte KM. C-509T polymorphism in the 
TGFB1 gene promoter: impact on Crohn’s disease susceptibility and clinical 
course? Immunogenetics (2001) 53(2):178–82. doi:10.1007/s002510100309 
82. Yamada Y, Miyauchi A, Goto J, Takagi Y, Okuizumi H, Kanematsu M, et al. 
Association of a polymorphism of the transforming growth factor-beta1 
gene with genetic susceptibility to osteoporosis in postmenopausal 
Japanese women. J Bone Miner Res (1998) 13(10):1569–76. doi:10.1359/
jbmr.1998.13.10.1569 
83. Grainger DJ, Heathcote K, Chiano M, Snieder H, Kemp PR, Metcalfe JC, 
et al. Genetic control of the circulating concentration of transforming growth 
factor type beta1. Hum Mol Genet (1999) 8(1):93–7. doi:10.1093/hmg/8.1.93 
84. García-González MA, Crusius JB, Strunk MH, Bouma G, Pérez-Centeno 
CM, Pals G, et  al. TGFB1 gene polymorphisms and inflammatory bowel 
disease. Immunogenetics (2000) 51(10):869–72. doi:10.1007/s002510000211 
12
Verstockt and Cleynen Genetics in Fibrostenotic Crohn’s Disease
Frontiers in Medicine | www.frontiersin.org May 2016 | Volume 3 | Article 24
85. Inoue I, Nakajima T, Williams CS, Quackenbush J, Puryear R, Powers M, 
et al. A nucleotide substitution in the promoter of human angiotensinogen is 
associated with essential hypertension and affects basal transcription in vitro. 
J Clin Invest (1997) 99(7):1786–97. doi:10.1172/JCI119343 
86. Huppertz B, Kertschanska S, Demir AY, Frank HG, Kaufmann P. 
Immunohistochemistry of matrix metalloproteinases (MMP), their 
substrates, and their inhibitors (TIMP) during trophoblast invasion in 
the human placenta. Cell Tissue Res (1998) 291(1):133–48. doi:10.1007/
s004410050987 
87. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodeling. 
Trends Genet (1990) 6(4):121–5. doi:10.1016/0168-9525(90)90126-Q 
88. Meijer MJ, Mieremet-Ooms MA, van Hogezand RA, Lamers CB, Hommes 
DW, Verspaget HW. Role of matrix metalloproteinase, tissue inhibitor of 
metalloproteinase and tumor necrosis factor-alpha single nucleotide gene 
polymorphisms in inflammatory bowel disease. World J Gastroenterol (2007) 
13(21):2960–6. doi:10.3748/wjg.v13.i21.2960 
89. Warnaar N, Hofker HS, Maathuis MH, Niesing J, Bruggink AH, Dijkstra 
G, et al. Matrix metalloproteinases as profibrotic factors in terminal ileum 
in Crohn’s disease. Inflamm Bowel Dis (2006) 12(9):863–9. doi:10.1097/01.
mib.0000231568.43065.ed 
90. Fujimoto T, Parry S, Urbanek M, Sammel M, Macones G, Kuivaniemi H, 
et al. A single nucleotide polymorphism in the matrix metalloproteinase-1 
(MMP-1) promoter influences amnion cell MMP-1 expression and risk 
for preterm premature rupture of the fetal membranes. J Biol Chem (2002) 
277(8):6296–302. doi:10.1074/jbc.M107865200 
91. Satsangi J, Chapman RW, Haldar N, Donaldson P, Mitchell S, Simmons 
J, et  al. A functional polymorphism of the stromelysin gene (MMP-3) 
influences susceptibility to primary sclerosing cholangitis. Gastroenterology 
(2001) 121(1):124–30. doi:10.1053/gast.2001.25527 
92. Zhi H, Wang H, Ren L, Shi Z, Peng H, Cui L, et al. Functional polymorphisms 
of matrix metallopeptidase-9 and risk of coronary artery disease in a Chinese 
population. Mol Biol Rep (2010) 37(1):13–20. doi:10.1007/s11033-009-9482-x 
93. Borghaei RC, Rawlings PL, Javadi M, Woloshin J. NF-kappaB binds to a 
polymorphic repressor element in the MMP-3 promoter. Biochem Biophys 
Res Commun (2004) 316(1):182–8. doi:10.1016/j.bbrc.2004.02.030 
94. Medley TL, Kingwell BA, Gatzka CD, Pillay P, Cole TJ. Matrix metallo-
proteinase-3 genotype contributes to age-related aortic stiffening through 
modulation of gene and protein expression. Circ Res (2003) 92(11):1254–61. 
doi:10.1161/01.RES.0000076891.24317.CA 
95. Samnegård A, Silveira A, Lundman P, Boquist S, Odeberg J, Hulthe J, 
et  al. Serum matrix metalloproteinase-3 concentration is influenced by 
MMP-3 -1612 5A/6A promoter genotype and associated with myocardial 
infarction. J Intern Med (2005) 258(5):411–9. doi:10.1111/j.1365-2796.2005. 
01561.x 
96. Alonso A, Domènech E, Julià A, Panés J, García-Sánchez V, Mateu PN, et al. 
Identification of risk loci for Crohn’s disease phenotypes using a genome-wide 
association study. Gastroenterology (2015) 148(4):794–805. doi:10.1053/j.
gastro.2014.12.030 
97. Benjamin J, Makharia GK, Ahuja V, Kalaivani M, Joshi YK. Intestinal per-
meability and its association with the patient and disease characteristics in 
Crohn’s disease. World J Gastroenterol (2008) 14(9):1399–405. doi:10.3748/
wjg.14.1399 
98. Prager M, Büttner J, Haas V, Baumgart DC, Sturm A, Zeitz M, et al. The JAK2 
variant rs10758669 in Crohn’s disease: altering the intestinal barrier as one 
mechanism of action. Int J Colorectal Dis (2012) 27(5):565–73. doi:10.1007/
s00384-011-1345-y 
99. Forni D, Cleynen I, Ferrante M, Cassinotti A, Cagliani R, Ardizzone S, et al. 
ABO histo-blood group might modulate predisposition to Crohn’s disease 
and affect disease behavior. J Crohns Colitis (2014) 8(6):489–94. doi:10.1016/j.
crohns.2013.10.014 
100. McGovern DP, Jones MR, Taylor KD, Marciante K, Yan X, Dubinsky M, 
et  al. Fucosyltransferase 2 (FUT2) non-secretor status is associated with 
Crohn’s disease. Hum Mol Genet (2010) 19(17):3468–76. doi:10.1093/hmg/
ddq248 
101. Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, 
et al. Genome-wide meta-analysis increases to 71 the number of confirmed 
Crohn’s disease susceptibility loci. Nat Genet (2010) 42(12):1118–25. 
doi:10.1038/ng.717 
102. Mäkivuokko H, Lahtinen SJ, Wacklin P, Tuovinen E, Tenkanen H, 
Nikkilä J, et  al. Association between the ABO blood group and the 
human intestinal microbiota composition. BMC Microbiol (2012) 12:94. 
doi:10.1186/1471-2180-12-94 
103. Henckaerts L, Van Steen K, Verstreken I, Cleynen I, Franke A, Schreiber S, 
et al. Genetic risk profiling and prediction of disease course in Crohn’s disease 
patients. Clin Gastroenterol Hepatol (2009) 7(9):972–980.e2. doi:10.1016/j.
cgh.2009.05.001 
104. Novacek G, Papay P, Miehsler W, Reinisch W, Lichtenberger C, Sunder-
Plassmann R, et  al. Are inherited thrombotic risk factors associated with 
fibrostenosis in Crohn’s disease? Inflamm Bowel Dis (2011) 17(12):2505–11. 
doi:10.1002/ibd.21648 
105. Van Deventer SJ. Tumour necrosis factor and Crohn’s disease. Gut (1997) 
40(4):443–8. doi:10.1136/gut.40.4.443 
106. Cantor MJ, Nickerson P, Bernstein CN. The role of cytokine gene 
polymorphisms in determining disease susceptibility and phenotype in 
inflammatory bowel disease. Am J Gastroenterol (2005) 100(5):1134–42. 
doi:10.1111/j.1572-0241.2005.40979.x 
107. Zipperlen K, Peddle L, Melay B, Hefferton D, Rahman P. Association of TNF-
alpha polymorphisms in Crohn disease. Hum Immunol (2005) 66(1):56–9. 
doi:10.1016/j.humimm.2004.10.004 
108. Sleegers K, Bettens K, De Roeck A, Van Cauwenberghe C, Cuyvers E, Verheijen 
J, et al. A 22-single nucleotide polymorphism Alzheimer’s disease risk score 
correlates with family history, onset age, and cerebrospinal fluid Abeta42. 
Alzheimers Dement (2015) 11(12):1452–60. doi:10.1016/j.jalz.2015.02.013 
109. Kugathasan S, Collins N, Maresso K, Hoffmann RG, Stephens M, Werlin SL, 
et al. CARD15 gene mutations and risk for early surgery in pediatric-onset 
Crohn’s disease. Clin Gastroenterol Hepatol (2004) 2(11):1003–9. doi:10.1016/
S1542-3565(04)00452-5 
110. Sun L, Roesler J, Rösen-Wolff A, Winkler U, Koch R, Thürigen A, et  al. 
CARD15 genotype and phenotype analysis in 55 pediatric patients with 
Crohn disease from Saxony, Germany. J Pediatr Gastroenterol Nutr (2003) 
37(4):492–7. doi:10.1097/00005176-200310000-00017 
111. Liberek A, Jakóbkiewicz-Banecka J, Kloska A, Świderska J, Kmieć Z, Łuczak 
G, et al. Clinical parameters of inflammatory bowel disease in children do 
not correlate with four common polymorphisms of the transforming growth 
factor β1 gene. Acta Biochim Pol (2011) 58(4):641–4. 
112. Strisciuglio C, Auricchio R, Martinelli M, Staiano A, Giugliano FP, Andreozzi 
M, et al. Autophagy genes variants and paediatric Crohn’s disease phenotype: 
a single-centre experience. Dig Liver Dis (2014) 46(6):512–7. doi:10.1016/j.
dld.2014.02.016 
113. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. 
Increasing incidence and prevalence of the inflammatory bowel diseases with 
time, based on systematic review. Gastroenterology (2012) 142(1):46–54.e42. 
doi:10.1053/j.gastro.2011.10.001 quiz e30. 
114. Ng SC, Tang W, Ching JY, Wong M, Chow CM, Hui AJ, et  al. Incidence 
and phenotype of inflammatory bowel disease based on results from the 
Asia-pacific Crohn’s and colitis epidemiology study. Gastroenterology (2013) 
145(1):158–165.e2. doi:10.1053/j.gastro.2013.04.007 
115. Mahurkar S, Banerjee R, Rani VS, Thakur N, Rao GV, Reddy DN, et  al. 
Common variants in NOD2 and IL23R are not associated with inflamma-
tory bowel disease in Indians. J Gastroenterol Hepatol (2011) 26(4):694–9. 
doi:10.1111/j.1440-1746.2010.06533.x 
116. Adeyanju O, Okou DT, Huang C, Kumar A, Sauer C, Galloway C, et  al. 
Common NOD2 risk variants in African Americans with Crohn’s disease are 
due exclusively to recent Caucasian admixture. Inflamm Bowel Dis (2012) 
18(12):2357–9. doi:10.1002/ibd.22944 
117. Zouiten-Mekki L, Kharrat M, Karoui S, Serghimi M, Fekih M, Matri S, et al. 
Tolllike receptor 4 (TLR4) polymorphisms in Tunisian patients with Crohn’s 
disease: genotype-phenotype correlation. BMC Gastroenterol (2009) 9:62. 
doi:10.1186/1471-230X-9-62 
118. Meddour Y, Chaib S, Bousseloub A, Kaddache N, Kecili L, Gamar L, et al. 
NOD2/CARD15 and IL23R genetic variability in 204 Algerian Crohn’s 
disease. Clin Res Hepatol Gastroenterol (2014) 38(4):499–504. doi:10.1016/j.
clinre.2014.02.003 
119. Yang SK, Park M, Lim J, Park SH, Ye BD, Lee I, et al. Contribution of IL23R 
but not ATG16L1 to Crohn’s disease susceptibility in Koreans. Inflamm Bowel 
Dis (2009) 15(9):1385–90. doi:10.1002/ibd.20921 
13
Verstockt and Cleynen Genetics in Fibrostenotic Crohn’s Disease
Frontiers in Medicine | www.frontiersin.org May 2016 | Volume 3 | Article 24
120. Yamazaki K, Takahashi A, Takazoe M, Kubo M, Onouchi Y, Fujino A, et al. 
Positive association of genetic variants in the upstream region of NKX2-3 with 
Crohn’s disease in Japanese patients. Gut (2009) 58(2):228–32. doi:10.1136/
gut.2007.140764 
121. Ernst A, Jacobsen B, Østergaard M, Okkels H, Andersen V, Dagiliene E, et al. 
Mutations in CARD15 and smoking confer susceptibility to Crohn’s disease 
in the Danish population. Scand J Gastroenterol (2007) 42(12):1445–51. 
doi:10.1080/00365520701427102 
122. Barreiro-de-Acosta M, Mendoza JL, Lana R, Domínguez-Muñoz JE, 
Díaz-Rubio M. NOD2/CARD15: geographic differences in the Spanish 
population and clinical applications in Crohn’s disease. Rev Esp Enferm Dig 
(2010) 102(5):321–6. doi:10.4321/S1130-01082010000500006 
123. Cho JH. The promise of epigenetics. Has it delivered new insights? Digest Dis 
(2016) 34(1–2):12–9. doi:10.1159/000442919 
124. Lin Z, Hegarty JP, Cappel JA, Yu W, Chen X, Faber P, et  al. Identification 
of disease-associated DNA methylation in intestinal tissues from patients 
with inflammatory bowel disease. Clin Genet (2011) 80(1):59–67. 
doi:10.1111/j.1399-0004.2010.01546.x 
125. Lin Z, Hegarty JP, Yu W, Cappel JA, Chen X, Faber PW, et al. Identification 
of disease-associated DNA methylation in B cells from Crohn’s disease and 
ulcerative colitis patients. Dig Dis Sci (2012) 57(12):3145–53. doi:10.1007/
s10620-012-2288-z 
126. Sadler T, Bhasin JM, Xu Y, Barnholz-Sloan J, Chen Y, Ting AH, et al. Genome-
wide analysis of DNA methylation and gene expression defines molecular 
characteristics of Crohn’s disease-associated fibrosis. Clin Epigenet (2016) 
8:30. doi:10.1186/s13148-016-0193-6 
127. Frigola J, Muñoz M, Clark SJ, Moreno V, Capellà G, Peinado MA. 
Hypermethylation of the prostacyclin synthase (PTGIS) promoter is a fre-
quent event in colorectal cancer and associated with aneuploidy. Oncogene 
(2005) 24(49):7320–6. doi:10.1038/sj.onc.1208883 
128. You J, Nguyen AV, Albers CG, Lin F, Holcombe RF. Wnt pathway-related gene 
expression in inflammatory bowel disease. Dig Dis Sci (2008) 53(4):1013–9. 
doi:10.1007/s10620-007-9973-3 
129. Hokari R, Kurihara C, Nagata N, Aritake K, Okada Y, Watanabe C, et  al. 
Increased expression of lipocalin-type-prostaglandin D synthase in ulcerative 
colitis and exacerbating role in murine colitis. Am J Physiol Gastrointest Liver 
Physiol (2011) 300(3):G401–8. doi:10.1152/ajpgi.00351.2010 
130. Lala S, Ogura Y, Osborne C, Hor SY, Bromfield A, Davies S, et al. Crohn’s 
disease and the NOD2 gene: a role for Paneth cells. Gastroenterology (2003) 
125(1):47–57. doi:10.1016/S0016-5085(03)00661-9 
131. Vermeire S, Wild G, Kocher K, Cousineau J, Dufresne L, Bitton A, et al. CARD15 
genetic variation in a Quebec population: prevalence, genotype-phenotype 
relationship, and haplotype structure. Am J Hum Genet (2002) 71(1):74–83. 
doi:10.1086/341124 
132. Dotan I. Disease behavior in adult patients: are there predictors for stricture 
or fistula formation? Dig Dis (2009) 27(3):206–11. doi:10.1159/000228551 
133. Cleynen I, Vermeire S. The genetic architecture of inflammatory bowel dis-
ease: past, present and future. Curr Opin Gastroenterol (2015) 31(6):456–63. 
doi:10.1097/MOG.0000000000000215 
134. Liu Z, Lee J, Krummey S, Lu W, Cai H, Lenardo MJ. The kinase LRRK2 is 
a regulator of the transcription factor NFAT that modulates the severity 
of inflammatory bowel disease. Nat Immunol (2011) 12(11):1063–70. 
doi:10.1038/ni.2113 
135. Lighthouse JK, Small EM. Transcriptional control of cardiac fibroblast plas-
ticity. J Mol Cell Cardiol (2016) 91:52–60. doi:10.1016/j.yjmcc.2015.12.016 
136. Lee J, Anderson C, Wesley E, Ahmad T, Edwards C, Parkes M, et  al. 
Identification of a polymorphism that predisposes to longitudinal disease 
behaviour in Crohn’s disease and may have prognostic utility (abstract). 5th 
Congress of ECCO. Capri (2010).
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2016 Verstockt and Cleynen. This is an open-access article distributed 
under the terms of the Creative Commons Attribution License (CC BY). The use, 
distribution or reproduction in other forums is permitted, provided the original 
author(s) or licensor are credited and that the original publication in this journal 
is cited, in accordance with accepted academic practice. No use, distribution or 
reproduction is permitted which does not comply with these terms.
